

Antonio González Martínez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1617847/publications.pdf>

Version: 2024-02-01

118
papers

13,781
citations

81434

41
h-index

25230

113
g-index

125
all docs

125
docs citations

125
times ranked

13802
citing authors

#	ARTICLE	IF	CITATIONS
1	Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context. <i>Future Oncology</i> , 2022, 18, 2505-2536.	1.1	4
2	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 154, 327-353.	0.3	96
3	Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 658-669.	1.2	5
4	Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 5518-5518.	0.8	2
5	LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort. <i>Journal of Clinical Oncology</i> , 2021, 39, 5538-5538.	0.8	1
6	Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 5514-5514.	0.8	3
7	A phase III, randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 617-622.	1.2	21
8	Final results from GCI/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	2.3	40
9	European Network of Gynaecological Oncological Trial Groups™ requirements for trials between academic groups and industry partners—a new Model D for drug and medical device development. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 730-734.	1.2	3
10	Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1603-1607.	1.2	4
11	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 819-824.	1.2	7
12	Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 379-385.	0.6	89
13	COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 561-563.	1.2	137
14	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>Gynecologic Oncology</i> , 2019, 154, 255-258.	0.6	7
15	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 99-106.	1.3	17
16	Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1050-1056.	1.2	39
17	Updates and management algorithm for neuroendocrine tumors of the uterine cervix. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 986-995.	1.2	71
18	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2391-2402.	13.9	1,337

#	ARTICLE	IF	CITATIONS
19	Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1141-1147.	1.2	11
20	Early-stage mucinous carcinoma (infiltrative type) of the ovary and fertility preservation. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 835-839.	1.2	0
21	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. <i>Annals of Oncology</i> , 2019, 30, 1080-1087.	0.6	456
22	Chemotherapy-free treatments: are we ready for prime time?. <i>Annals of Oncology</i> , 2019, 30, 497-498.	0.6	2
23	GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. <i>Future Science OA</i> , 2019, 5, FSO370.	0.9	6
24	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1094-1097.	1.2	6
25	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	13.9	1,176
26	Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?. <i>Cancer</i> , 2019, 125, 4616-4622.	2.0	42
27	Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 628-635.	0.7	9
28	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 53-60.	0.6	40
29	Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1076-1084.	1.2	9
30	OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 431-438.	0.6	54
31	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2018, 20, 274-285.	1.2	5
32	SEOM clinical guidelines for endometrial cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 29-37.	1.2	27
33	OV21/PETROC: A Randomized Gynecologic Cancer Intergroup Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery in Epithelial Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 209-210.	0.2	0
34	Is there a role for HIPEC in ovarian cancer?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 859-860.	0.8	6
35	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2495-2505.	13.9	1,854
36	Safety and dose modification for patients receiving niraparib. <i>Annals of Oncology</i> , 2018, 29, 1784-1792.	0.6	125

#	ARTICLE	IF	CITATIONS
37	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 46-52.	0.6	48
38	HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?. <i>Annals of Oncology</i> , 2018, 29, 1610-1613.	0.6	40
39	Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)â€™Initial safety and efficacy from expansion cohorts (ECs) of phase I study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 195-195.	0.8	5
40	Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. <i>Annals of Oncology</i> , 2017, 28, 1280-1287.	0.6	42
41	Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?. <i>Lancet Oncology</i> , The, 2017, 18, 8-9.	5.1	12
42	Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice. <i>Future Oncology</i> , 2017, 13, 3-9.	1.1	10
43	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 50-58.	1.2	61
44	Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv72-iv83.	0.6	604
45	18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1432-1441.	3.2	32
46	Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. <i>Gynecologic Oncology</i> , 2017, 144, 65-71.	0.6	21
47	Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. <i>Annals of Oncology</i> , 2017, 28, viii30-viii35.	0.6	32
48	Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5506-5506.	0.8	13
49	Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)â€™(GEICO 1205/NOVA TRIAL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5508-5508.	0.8	11
50	Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5553-5553.	0.8	5
51	The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5560-5560.	0.8	5
52	PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5605-TPS5605.	0.8	3
53	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017, 8, 21472-21482.	0.8	14
54	Minimal Macroscopic Residual Disease (0.1â€™1 cm). Is It Still a Surgical Goal in Advanced Ovarian Cancer?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 906-911.	1.2	20

#	ARTICLE	IF	CITATIONS
55	Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 898-905.	1.2	4
56	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 2-30.	1.2	515
57	SEOM Clinical Guideline in ovarian cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1206-1212.	1.2	15
58	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 142, 62-69.	0.6	70
59	What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1666-1673.	0.7	43
60	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , 2016, 387, 1066-1074.	6.3	216
61	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2154-2164.	13.9	1,860
62	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 2336-2342.	2.3	69
63	Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. <i>European Journal of Cancer</i> , 2016, 69, 127-134.	1.3	49
64	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). <i>Annals of Oncology</i> , 2016, 27, 2236-2241.	0.6	32
65	Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 3-10.	1.1	5
66	FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. <i>Gynecologic Oncology</i> , 2016, 142, 597-607.	0.6	64
67	Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). <i>Journal of Clinical Oncology</i> , 2016, 34, 2516-2525.	0.8	60
68	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, 16-41.	0.6	862
69	Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. <i>Journal of Clinical Oncology</i> , 2016, 34, 1584-1593.	0.8	108
70	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 56295-56308.	0.8	83
71	Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. <i>BMC Cancer</i> , 2015, 15, 940.	1.1	16
72	El cáncer ginecológico. <i>Arbor</i> , 2015, 191, a237.	0.1	1

#	ARTICLE	IF	CITATIONS
73	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 559-581.	0.3	167
74	SEOM guidelines for cervical cancer. <i>Clinical and Translational Oncology</i> , 2015, 17, 1036-1042.	1.2	27
75	A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 136, 130-135.	0.6	80
76	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2015, 31, 1129-1137.	0.9	37
77	SEOM guideline in ovarian cancer 2014. <i>Clinical and Translational Oncology</i> , 2014, 16, 1067-1071.	1.2	13
78	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 689-699.	5.1	595
79	Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for) Tj ETQq1 1 0.784314 rgBT /Ov	1.3	9
80	Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: Results of the CNIO-BR002 phase I trial. <i>Molecular Oncology</i> , 2014, 8, 1719-1728.	2.1	3
81	Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). <i>British Journal of Cancer</i> , 2014, 111, 1060-1064.	2.9	26
82	First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions. <i>Drugs</i> , 2014, 74, 879-889.	4.9	20
83	Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. <i>Clinical and Translational Oncology</i> , 2013, 15, 477-483.	1.2	12
84	Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. <i>European Journal of Cancer</i> , 2013, 49, 3831-3838.	1.3	48
85	Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. <i>Annals of Oncology</i> , 2013, 24, 3028-3034.	0.6	66
86	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013, 13, 421-432.e8.	1.1	104
87	Emerging Concerns When Evidence-Based Medicine Is Translated into Real Life: The Case of Neoadjuvant Chemotherapy in Ovarian Cancer. <i>Current Oncology Reports</i> , 2013, 15, 4-6.	1.8	2
88	Bevacizumab as front-line treatment for newly diagnosed epithelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 123-129.	1.1	6
89	Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi24-vi32.	0.6	721
90	Update on randomized trials on recurrent disease. <i>Annals of Oncology</i> , 2013, 24, x48-x52.	0.6	9

#	ARTICLE	IF	CITATIONS
91	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. <i>Journal of Clinical Oncology</i> , 2012, 30, 3444-3447.	0.8	18
92	Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. <i>Annals of Oncology</i> , 2012, 23, 1130-1137.	0.6	60
93	Ovarian low-grade serous carcinoma: A comprehensive update. <i>Gynecologic Oncology</i> , 2012, 126, 279-285.	0.6	92
94	Feasibility of a Modified Outpatient Regimen of Intravenous/Intraperitoneal Chemotherapy in Optimally Debulked Stage III Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1048-1055.	1.2	11
95	Early-stage ovarian cancer management: still a challenge. <i>Clinical and Translational Oncology</i> , 2011, 13, 67-68.	1.2	1
96	Current management of uterine sarcomas. <i>Clinical and Translational Oncology</i> , 2011, 13, 307-314.	1.2	13
97	Clinical Trials in Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 771-775.	1.2	186
98	Risk Factors for Node Affection and Recurrence in Endometrial Cancer. <i>Current Women's Health Reviews</i> , 2011, 7, 320-325.	0.1	0
99	Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting. <i>Clinical and Translational Oncology</i> , 2010, 12, 418-430.	1.2	6
100	Targeting cytoskeleton reorganisation as antimetastatic treatment. <i>Clinical and Translational Oncology</i> , 2010, 12, 662-669.	1.2	12
101	The relevance of the Spanish society for medical oncology (SEOM)'s clinical oncology guidelines. <i>Clinical and Translational Oncology</i> , 2010, 12, 707-708.	1.2	3
102	Adjuvant endocrine therapy in premenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 43-47.	1.1	5
103	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <i>Annals of Oncology</i> , 2010, 21, 195-198.	0.6	41
104	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009, 11, 363-375.	1.2	15
105	Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. <i>Clinical and Translational Oncology</i> , 2009, 11, 589-595.	1.2	19
106	Lights and shadows of the tumoral marker CA-125 in ovarian cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 449-452.	1.2	1
107	The current role of neoadjuvant chemotherapy in the management of cervical carcinoma. <i>Gynecologic Oncology</i> , 2008, 110, S36-S40.	0.6	57
108	Surgical treatment of recurrent cervical cancer: State of the art and new achievements. <i>Gynecologic Oncology</i> , 2008, 110, S60-S66.	0.6	38

#	ARTICLE	IF	CITATIONS
109	Indications for adjuvant radiotherapy treatment after surgery and novel modalities for treatment. <i>Gynecologic Oncology</i> , 2008, 110, S41-S44.	0.6	11
110	Novel chemotherapy approaches in chemoradiation protocols. <i>Gynecologic Oncology</i> , 2008, 110, S45-S48.	0.6	14
111	Sparing fertility in young patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2008, 111, S101-S104.	0.6	114
112	Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update. <i>Annals of Oncology</i> , 2008, 19, vii70-vii76.	0.6	9
113	Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients. <i>Clinical and Translational Oncology</i> , 2007, 9, 323-328.	1.2	3
114	Lack of Association Between NOS3 Glu298Asp and Breast Cancer Risk: a Case-control Study. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 331-333.	1.1	21
115	Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study. <i>Annals of Oncology</i> , 2005, 16, 749-755.	0.6	106
116	Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment?. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 185-191.	1.2	7
117	Ifosfamide and Vinorelbine in Advanced Platinum-Resistant Ovarian Cancer: Excessive Toxicity with a Potentially Active Regimen. <i>Gynecologic Oncology</i> , 2002, 84, 368-373.	0.6	20
118	Metastatic Endometrial Cancer in Lung and Liver: Complete and Prolonged Response to Hormonal Therapy with Progestins. <i>Gynecologic Oncology</i> , 1999, 72, 250-255.	0.6	10